Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004)

Veterinary and Comparative Oncology

Volumn 5, Issue 3, 2007, Pages 156-167

  Camps Palau, M A ^a   Leibman, Nicole F ^b   Elmslie, R ^c   Lana, S E ^d   Plaza, S ^d   McKnight, J A ^b   Risbon, R ^e   Bergman, P J ^b  

^a City Veterinary Care   (United States)

^b ANIMAL MEDICAL CENTER   (United States)

^c Veterinary Referral Center of Colorado   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e RED BANK VETERINARY HOSPITAL   (United States)

Author keywords

Canine; Cyclophosphamide; Mast cell tumour; Prednisone; Vinblastine

Indexed keywords

CANIS FAMILIARIS;

EID: 42449153345     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2006.00125.x     Document Type: Article

References (41)

1. Vail DM. Mast cell tumors. In: Small Animals Clinical Oncology, 2 nd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, PA, WB Saunders, 1995: 192-210.
2. Patnaik AK, Ehler WJ and MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology 1984; 21: 469-474.
3. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice 1973; 14: 27-40.
4. Hottendorf GH and Nielsen SW. Survey of 300 extirpated canine mastocytomas. Zentralblatt Veterinarmedizin A 1967; 14: 272-281.
5. Turrel JM, Kitchell BE, Miller LM and Theon A. Prognostic factors for radiation treatment of mast cell tumors in 85 dogs. Journal of the American Veterinary Medical Association 1988; 193: 936-940.
6. O'Keefe DA. Canine mast cell tumors. The Veterinary Clinics of North America. Small Animal Practice 1990; 20: 1105-1115.
7. Ogilvie G and Moore A. Mast Cell Tumors. Managing the Veterinary Cancer Patient: A Practice Manual. Trenton, NJ, Veterinary Learning Systems Co, Inc, 1996: 503-514.
8. McCaw DL, Miller MA, Ogilvie GK, Withrow SJ, Brewer WG Jr, Klein MK, Bell FW and Anderson SK. Response of canine mast cell tumors to treatment with oral prednisone. Journal of Veterinary Internal Medicine 1994; 8: 406-408.
9. McCaw DL, Miller MA, Bergman PJ, Withrow SJ, Moore AS, Knapp DW, Fowler D and Johnson JC. Vincristine therapy for mast cell tumors in dogs. Journal of Veterinary Internal Medicine 1997; 11: 375-378.
10. Thamm DH, Mauldin EA and Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999; 13: 491-497.
11. Davies DR, Wyatt KM, Jardine JE, Robertson ID and Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. Journal of the American Animal Hospital Association 2004; 40: 124-130.
12. Thamm DH, Turek MM and Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006; 6: 581-587.
13. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ and Cotter SM. Treatment of canine mast cell tumors with CCNU (Lomustine). Journal of Veterinary Internal Medicine 1999; 13: 601-605.
14. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Hereux DA and Frimberger AE. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine 1999; 13: 395-398.
15. Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretin JD, Morrison-Collister K, Cotter SM and Moore AS. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. Journal of Veterinary Internal Medicine 2004; 18: 75-80.
16. Golden DL and Langston VC. Uses of vincristine and vinblastine in dogs and cats. Journal of the American Veterinary Medical Association 1988; 193: 1114-1117.
17. Rowinsky EK and Donehower RC. Antimicrotubule agents. In: Cancer: Principles and Practice of Oncology, 5th edn., VT DeVita, S Hellman and SA Rosenberg, eds., Philadelphia, PA, Lippincott-Raven, 1997: 468.
18. Stanton ME and Legendre AM. Effects of cyclophosphamide in dogs and cats. Journal of the American Veterinary Medical Association 1986; 188: 1319-1322.
19. Plumb DC. Veterinary Drug Handbook Pocket Edition, 2nd edn., White Bear Lake, MN, PharmaVet Publishing, 1995: 173-176.
20. Charney SC, Bergman PJ, Hohenhaus AE and McKnight JA. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). Journal of the American Veterinary Medical Association 2003; 222: 1388-1393.
21. Veterinary Co-operative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats version 1.0. Veterinary and Comparative Oncology 2004; 2: 194-213.
22. Fleming TR and Lin DY. Survival analysis in clinical trials: Past developments and future directions. Biometrics 2000; 56: 971-983.
23. Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA and Patnaik AK. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2004; 224: 236-240.
24. Fulcher RP, Ludwig LL, Bergman PJ, Newman SJ, Simpson AM and Patnaik AK. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2006; 228: 210-215.
25. Al-Sarraf R, Mauldin GN, Patnaik AK and Meleo KA. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. Journal of Veterinary Internal Medicine 1996; 10: 376-378.
26. Seguin B, Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell WS, Fettman MJ and Withrow SJ. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). Journal of the American Veterinary Medical Association 2001; 7: 1120-1123.
27. Seguin B, Besancon MF, McCallan JL, Dewe LL, Tenwolde MC, Wong EK and Kent MS. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). Journal of Veterinary Internal Medicine 2006; 20: 933-940.
28. Weisse C, Shofer FS and Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. Journal of the American Animal Hospital Association 2002; 1: 71-73.
29. Frimberger AE, Moore AS, LaRue SM, Gliatto JM and Bengtson AE. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993). Journal of the American Animal Hospital Association 1997; 33: 320-324.
30. LaDue T, Price GS, Dodge R, Page RL and Thrall DE. Radiation therapy for incompletely resected canine mast cell tumors. Veterinary Radiology & Ultrasound 1998; 1: 57-62.
31. Misdrop W. Incomplete surgery, local immunostimulation and recurrence of some tumor types in dogs and cats. Veterinary Quarterly 1987; 9: 279-286.
32. Michels GM, Knapp DW, DeNicola DB, Glickman N and Bonney P. Prognosis following surgical ecxision of canine cutaneous mast cell tumors with hispopathologically tumor-free versus nontumor-free margins: A retrospective study of 31 cases. Journal of the American Animal Hospital Association 2002; 38: 458-466.
33. Murphy S, Sparkes AH, Smith KC, Blunden AS and Brearley MJ. Relationships between the histological grade of cutaneous mast cell tumors in dogs, their survival and the efficacy of surgical resection. Veterinary Record 2004; 154: 743-746.
34. Bostock DE, Crocker D, Harris K and Smith P. Nucleolar organizer regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumors. British Journal of Cancer 1989; 59: 915-918.
35. Kravis LD, Vail DM, Kisseberth WC, Ogilvie GK and Volk LM. Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. Journal of the American Veterinary Medical Association 1996; 209: 1418-1420.
36. Simoes JPC, Schoning P and Butine M. Prognosis of canine mast cell tumors: A comparison of three methods. Veterinary Pathology 1994; 31: 637-647.
37. Scase TJ, Edwards D, Miller J, Henley W, Smith K, Blunden A and Murphy S. Canine mast cell tumors: Correlation of apoptosis and proliferation markers with prognosis. Journal of Veterinary Internal Medicine 2006; 20: 151-158.
38. Ayl RD, Couto CG, Hammer AS, Weisbrode S, Ericson JG and Mathes L. Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumors. Veterinary Pathology 1992; 29: 386-390.
39. Sakai H, Noda A, Shirai N, Iidaka T, Yanai T, Masegi T, Shirai N, Idiaka T, Yanai T and Masegi T. Proliferation activity of canine mast cell tumors evaluated by bromodeoxyuridine incorporation and Ki-67 expression. Journal of Comparative Patholology 2002; 127: 233-238.
40. O'Keefe DA, Couto CG, Burke-Schwartz C and Jacobs RM. Systemic mastocytosis in 16 dogs. Journal of Veterinary Internal Medicine 1987; 2: 75-80.
41. Hahn KA, King GK and Carreras JK. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998). Journal of the American Veterinary Medical Association 2004; 224: 79-82.